Spark Avoids Igniting Pricing Firestorm With Savvy Launch Messages

 
• By Michael McCaughan

US launch of gene therapy Luxturna could set tone for attention to extremely high priced therapies in 2018. So far, company seems to be doing things right.

Sparks
Spark seems unlikely to get burned by its pricing strategy. • Source: Tom Bullock

More from Pricing Debate

More from Market Access